Shares of Pfizer rose 4.24% to $41.08 at 09:44 EST on Wednesday, after two sequential sessions in a row of gains. The New York Stock Exchange is jumping 1% to $14,146.60, following yesterday’s upward trend, on what up to now seems, a somewhat positive trend trading session today.

Pfizer’s last close was $38.31, 1.43% under its 52-week high of $40.50.

News about Pfizer today

Pfizer-biontech coronavirs vaccine gains approval for use in the UK. According to today’s article on ForexLive, “UK says that the vaccine will be made available starting from next week. This has been widely anticipated but it adds to the optimism and buzz surrounding vaccine developments.”

Pfizer says US FDA and EU EMA decisions on authorisation expected this month as well. According to today’s article on ForexLive, “Pfizer briefs after the UK MHRA authorises emergency-use supply for its coronavirus vaccine
The pharmaceutical firm also confirms that companies are ready to deliver the first doses to the UK immediately.”

Pfizer, biontech’s covid-19 vaccine wins u.k. authorization. According to today’s article on The Wall Street Journal, “Britain became the first Western nation to grant emergency-use authorization for a Covid-19 vaccine, clearing a shot developed by Pfizer and Germany’s BioNTech to be distributed in limited numbers within days..”

Pfizer’s Sales

Pfizer’s sales growth is a negative 9.7% for the ongoing quarter and a decline by 9.1% for the next. The company’s growth estimates for the current quarter and the next is a negative 12.7% and a negative 12.5%, respectively.

Pfizer’s Revenue

Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.

Pfizer’s Stock Top and Bottom Yearly Value

Pfizer’s stock is valued at $41.08 at 09:44 EST, above its 52-week high of $40.50.

Pfizer’s Moving Average

Pfizer’s value is way above its 50-day moving average of $35.66 and way higher than its 200-day moving average of $34.81.

Previous days news about Pfizer

According to yesterday’s article on Bloomberg Quint, “Pfizer, BioNTech Seek Clearance to Sell Covid Vaccine in Europe.”

According to yesterday’s article on Bloomberg Quint, “Pfizer, biontech seek EU clearance for covid-19 vaccine.”

Pfizer-biontech seeks EU clearance for coronavirus vaccine. According to yesterday’s article on ForexLive, “Pfizer vaccine can be in use in the EU by the year-end if cleared. Pfizer-BioNTech just announced that they have submitted an application to the EMA today to seek clearance for coronavirus vaccine use in the EU.”

According to yesterday’s article on The Wall Street Journal, “Pfizer and partner BioNTech said they are seeking approval from the European Union for their coronavirus vaccine.”


Please enter your comment!
Please enter your name here